期刊
CARDIOVASCULAR RESEARCH
卷 117, 期 13, 页码 2624-2638出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvab259
关键词
heart transplantation; chronic rejection; innate and adaptive immunity; endothelial cells; vascular smooth muscle cells
资金
- National Institutes of Health [HL109420, U01AI132895, R01 HL146723, R01 HL152197, P01HL018646, P01AI123086, U01AI131470, R01AI165879]
- Heart and Stroke Foundation Canada Ontario Clinician Scientist Phase I award
- Tier 2 University of Ottawa Clinical Research Chair in Cardiac Transplantation
This article discusses the incidence and diagnosis, the nature of the vascular remodelling, immune and non-immune contributions to pathogenesis, current therapies, and future areas of research in cardiac allograft vasculopathy (CAV).
Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late graft loss. Although best understood following cardiac transplantation, similar forms of allograft vasculopathy occur in other vascularized organ grafts and some features of CAV may be shared with other immune-mediated vasculopathies. Here, we describe the incidence and diagnosis, the nature of the vascular remodelling, immune and non-immune contributions to pathogenesis, current therapies, and future areas of research in CAV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据